Rx Statin Critic Predicts Safer Use In Lower-Dose Switch OTCs
This article was originally published in The Tan Sheet
Executive Summary
Duane Graveline says drug firms “are going to realize” they will not “get any support from people who understand” the full range of statin adverse effects. “Tens of thousands of statin users” report weakness, instability, easy fatigue, muscle aches and pains, depression, personality change and faulty memory, he says.
You may also be interested in...
Room For Innovative Switches Could Lurk In Existing FDA Framework
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.
Pfizer Lipitor OTC Bid Would Face FDA Evolving On Switch Innovation
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.